Damora Therapeutics, Inc. — Form 8-K Summary
Event date: April 28, 2026. The report was signed May 4, 2026. Damora Therapeutics, Inc. (Nasdaq: DMRA) reported changes to its finance leadership, effective May 1, 2026.
Leadership changes and compensation
- Lori Firmani will cease serving as Chief Financial Officer. She had served as principal financial officer and principal accounting officer since August 2024, before the company’s acquisition of privately held Damora Therapeutics in November 2025.
- Subject to signing and not revoking a separation agreement and general release, Firmani is eligible for benefits under the company’s Executive Separation Benefits Plan. The filing states that base-salary continuation and a prorated target bonus will be paid as a lump sum, she will receive a $6,000 health savings account contribution, and all outstanding equity awards will be fully accelerated.
- Brian Burkavage, the company’s Senior Vice President, Finance, was appointed principal financial officer and principal accounting officer effective May 1. His background includes finance and accounting roles at IO Biotech, Passage Bio, and Aclaris Therapeutics, as well as 11 years at Ernst & Young. He is a licensed CPA.
- Burkavage will enter into the company’s standard executive-officer indemnification agreement. The filing reports no family relationships or disclosable related-party transactions involving him.
Financial information and outlook
This 8-K reports personnel changes, not financial results. It provides no revenue, profit, cash flow, margin, debt, liquidity, or forward-guidance figures, and does not quantify the total financial impact of Firmani’s separation benefits or equity acceleration.
Key facts for investors to verify
- Whether Firmani executes and does not revoke the required separation agreement and release.
- Completion of the CFO and principal financial and accounting officer transition effective May 1, 2026.
- The resulting compensation and equity-award expense, which is not quantified in this filing.